CR Pharma’s Dong-E-E-Jiao Posts 7.1% Profit Growth in Q1 2026, Cash Reserves Surge

Bulletin Express04-24

China Resources Pharmaceutical Group Limited (CR Pharma; 03320) reported unaudited first-quarter 2026 results for its consolidated subsidiary Dong-E-E-Jiao.

Financial highlights for the three months ended 31 March 2026 (PRC GAAP, unaudited):

• Revenue reached RMB 1.81 billion, up 5.5% from RMB 1.72 billion in the prior-year period.

• Net profit rose 7.1% year on year to RMB 454.77 million.

• Net cash inflow from operating and investing activities expanded to RMB 1.22 billion, markedly higher than RMB 390.67 million a year earlier.

• Cash and cash equivalents closed the quarter at RMB 4.62 billion, versus RMB 3.12 billion at the end of Q1 2025.

Balance-sheet snapshot (as at 31 March 2026):

• Total assets stood at RMB 13.55 billion, up 1.3% from 31 December 2025.

• Total liabilities fell 10.1% to RMB 2.71 billion, lowering the liability-to-asset ratio to roughly 20.0%.

• Owner’s equity increased to RMB 10.84 billion from RMB 10.36 billion at 2025 year-end.

Ownership structure:

CR Pharma holds a 10.19% direct stake in Dong-E-E-Jiao and controls a further 13.31% through its non-wholly-owned subsidiary, China Resources Dong-E-E-Jiao Company Limited, giving the Group an effective interest of approximately 23.50%.

The figures are unaudited and may be adjusted during the annual audit process. Investors are advised to consult the full quarterly filing on the Shenzhen Stock Exchange website for comprehensive details.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1104700735?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-24 17:45","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1104700735","market":"us","top_or_hot":-1,"title":"CR Pharma’s Dong-E-E-Jiao Posts 7.1% Profit Growth in Q1 2026, Cash Reserves Surge","media":"Bulletin Express","content":"<p>China Resources Pharmaceutical Group Limited (CR Pharma; 03320) reported unaudited first-quarter 2026 results for its consolidated subsidiary Dong-E-E-Jiao.</p>\n<p>Financial highlights for the three months ended 31 March 2026 (PRC GAAP, unaudited):</p>\n<p>• Revenue reached RMB 1.81 billion, up 5.5% from RMB 1.72 billion in the prior-year period.</p>\n<p>• Net profit rose 7.1% year on year to RMB 454.77 million.</p>\n<p>• Net cash inflow from operating and investing activities expanded to RMB 1.22 billion, markedly higher than RMB 390.67 million a year earlier.</p>\n<p>• Cash and cash equivalents closed the quarter at RMB 4.62 billion, versus RMB 3.12 billion at the end of Q1 2025.</p>\n<p>Balance-sheet snapshot (as at 31 March 2026):</p>\n<p>• Total assets stood at RMB 13.55 billion, up 1.3% from 31 December 2025.</p>\n<p>• Total liabilities fell 10.1% to RMB 2.71 billion, lowering the liability-to-asset ratio to roughly 20.0%.</p>\n<p>• Owner’s equity increased to RMB 10.84 billion from RMB 10.36 billion at 2025 year-end.</p>\n<p>Ownership structure:</p>\n<p>CR Pharma holds a 10.19% direct stake in Dong-E-E-Jiao and controls a further 13.31% through its non-wholly-owned subsidiary, China Resources Dong-E-E-Jiao Company Limited, giving the Group an effective interest of approximately 23.50%.</p>\n<p>The figures are unaudited and may be adjusted during the annual audit process. Investors are advised to consult the full quarterly filing on the Shenzhen Stock Exchange website for comprehensive details.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CR Pharma’s Dong-E-E-Jiao Posts 7.1% Profit Growth in Q1 2026, Cash Reserves Surge</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCR Pharma’s Dong-E-E-Jiao Posts 7.1% Profit Growth in Q1 2026, Cash Reserves Surge\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-04-24 17:45</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>China Resources Pharmaceutical Group Limited (CR Pharma; 03320) reported unaudited first-quarter 2026 results for its consolidated subsidiary Dong-E-E-Jiao.</p>\n<p>Financial highlights for the three months ended 31 March 2026 (PRC GAAP, unaudited):</p>\n<p>• Revenue reached RMB 1.81 billion, up 5.5% from RMB 1.72 billion in the prior-year period.</p>\n<p>• Net profit rose 7.1% year on year to RMB 454.77 million.</p>\n<p>• Net cash inflow from operating and investing activities expanded to RMB 1.22 billion, markedly higher than RMB 390.67 million a year earlier.</p>\n<p>• Cash and cash equivalents closed the quarter at RMB 4.62 billion, versus RMB 3.12 billion at the end of Q1 2025.</p>\n<p>Balance-sheet snapshot (as at 31 March 2026):</p>\n<p>• Total assets stood at RMB 13.55 billion, up 1.3% from 31 December 2025.</p>\n<p>• Total liabilities fell 10.1% to RMB 2.71 billion, lowering the liability-to-asset ratio to roughly 20.0%.</p>\n<p>• Owner’s equity increased to RMB 10.84 billion from RMB 10.36 billion at 2025 year-end.</p>\n<p>Ownership structure:</p>\n<p>CR Pharma holds a 10.19% direct stake in Dong-E-E-Jiao and controls a further 13.31% through its non-wholly-owned subsidiary, China Resources Dong-E-E-Jiao Company Limited, giving the Group an effective interest of approximately 23.50%.</p>\n<p>The figures are unaudited and may be adjusted during the annual audit process. Investors are advised to consult the full quarterly filing on the Shenzhen Stock Exchange website for comprehensive details.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"03320","symbol_name":"华润医药","start_time":0,"source_url":"","article_id":"1104700735","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1104700735","pubTimestamp":1777023949,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"China Resources Pharmaceutical Group Limited (CR Pharma; 03320) reported unaudited first-quarter 2026 results for its consolidated subsidiary Dong-E-E-Jiao. Financial highlights for the three months...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"03320":"华润医药"},"translate_title":"华润医药东阿阿胶2026年第一季度利润增长7.1%，现金储备激增","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03320":1},"content_text":"China Resources Pharmaceutical Group Limited (CR Pharma; 03320) reported unaudited first-quarter 2026 results for its consolidated subsidiary Dong-E-E-Jiao.\nFinancial highlights for the three months ended 31 March 2026 (PRC GAAP, unaudited):\n• Revenue reached RMB 1.81 billion, up 5.5% from RMB 1.72 billion in the prior-year period.\n• Net profit rose 7.1% year on year to RMB 454.77 million.\n• Net cash inflow from operating and investing activities expanded to RMB 1.22 billion, markedly higher than RMB 390.67 million a year earlier.\n• Cash and cash equivalents closed the quarter at RMB 4.62 billion, versus RMB 3.12 billion at the end of Q1 2025.\nBalance-sheet snapshot (as at 31 March 2026):\n• Total assets stood at RMB 13.55 billion, up 1.3% from 31 December 2025.\n• Total liabilities fell 10.1% to RMB 2.71 billion, lowering the liability-to-asset ratio to roughly 20.0%.\n• Owner’s equity increased to RMB 10.84 billion from RMB 10.36 billion at 2025 year-end.\nOwnership structure:\nCR Pharma holds a 10.19% direct stake in Dong-E-E-Jiao and controls a further 13.31% through its non-wholly-owned subsidiary, China Resources Dong-E-E-Jiao Company Limited, giving the Group an effective interest of approximately 23.50%.\nThe figures are unaudited and may be adjusted during the annual audit process. Investors are advised to consult the full quarterly filing on the Shenzhen Stock Exchange website for comprehensive details.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1104700735","isCrawlerRequest":true}